The key to improve the therapeutic efficacy for cancer treatment is to increase the delivery of drugs to tumors. For this purpose, tumor-microenvironment stimuliresponsive materials have great potential. Here, we prepared a new nanomedicine by bonding the conjugate of honokiol (HNK) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to a glutathione (GSH)-responsive nanocarrier, poly(α-lipoic acid) polyethylene glycol. The nanomedicine would disintegrate due to the high level of GSH at the tumor sites, achieving the co-delivery of HNK and DMXAA, and realizing the combination therapy through close-range killing by HNK and long-range striking by DMXAA together. In a murine 4T1 breast tumor model, this strategy exhibited high tumor inhibition rate of 93%, and provided a valuable therapeutic choice for cancer therapy. Figure 7 Anticancer efficiency and body weight changes in vivo. (a) Tumor volume and (b) body weight changes during therapy; (c) tumor images at the end of treatment; (d) injection schedule for all groups. Scale bar: 10 mm.
INTRODUCTION
The combination therapy in cancer treatment achieved rapid development in both research and clinical practice [1, 2] . As we all know, due to the poor permeability of cytotoxic drugs in solid tumors, more and more attention has been paid to the combination therapy consisting of vascular disrupting agents (VDAs) [3, 4] , which can block the nutrients and oxygen supply by destroying the tumor vessels. As one of the most famous leading VDAs, 5,6dimethylxanthenone-4-acetic acid (DMXAA) [5, 6] can induce hemorrhagic necrosis due to the ability to inhibit blood flow selectively at the tumor sites, which can increase vascular endothelial apoptosis, induce coordinated decreases in tumor blood flow and enhance vascular permeability of tumors. As VDAs can cause extensive and concentrated necrosis of the tumors and eventually achieve the long-range strike of the tumors, which just makes up for the shortcomings of cytotoxic drugs that cannot penetrate into the tumor center sufficiently, the combination strategy of VDAs and cytotoxic drugs in the treatment of cancer has achieved encouraging results [7, 8] .
Tumor-microenvironment responsive nanocarriers have shown great potentials to increase the delivery of drugs to tumors [9] [10] [11] . Considering that both cytotoxic drugs and VDAs need to reach the tumor site to produce a marked effect, we can use the tumor-microenvironment-responsive nanocarriers to enhance the selective release of cytotoxic drugs and VDAs at the tumor sites. According to the characteristics of tumor microenvironment, such as enzymes [12] and pH [13] [14] [15] differences, high reactive oxygen species (ROS) [16] [17] [18] and L-glutathione (GSH) [19] level, various stimuli-responsive nanocarriers have been designed. Of these aspects, as the GSH concentration of the malignant tissues is at least four-fold higher than that of the normal tissues [20] [21] [22] , and the intracellular concentration of GSH is much higher than that in most extracellular fluids [23, 24] , many new GSH responsive nanoparticles achieved selective release of drugs at tumors [25] . However, most of them were prepared by complex process, such as modifying side groups [26] . In our recent study, GSH responsive nanocarriers were simply prepared by the ringopening polymerization (ROP) of alpha-lipoic acid [27] .
Herein, based on our previous work, we hypothesized that the combination of cytotoxic drugs and VDAs can achieve improved anti-tumor effect with selective release by GSH response in tumors. Honokiol (HNK), one ancient analogue of traditional Chinese medicine extracts, was chosen as a cytotoxic drug to form the conjugate with DMXAA (HNK-DMXAA) by chemical bonding. After the ROP of DL-alpha-lipoic acid (ALA) to obtain poly (alpha-lipoic acid) (PALA) [28, 29] and subsequent PE-Gylation to obtain PEGylated poly(alpha-lipoic acid) copolymer (PALA-g-mPEG) in a simple way, the HNK-DMXAA conjugate was grafted to PALA-g-mPEG to obtain the H-D NPs. When the H-D NPs arrived at the tumor tissues with high GSH concentration, HNK and DMXAA were released together due to the disintegration of the nanomedicine. Then DMXAA would block the blood supply and starve tumors to achieve internal necrosis, and HNK would kill the residual cells to achieve external death, which can realize the coordinated treatment of tumors, ultimately ( Fig. 1 ).
EXPERIMENTAL SECTION

Materials
Poly(ethylene glycol) monomethyl ether (M n = 5000 g mol −1 ) (mPEG 5k ), ALA and reduced GSH were purchased from Sigma-Aldrich LLC (China Characterization 1 H NMR spectra were measured on a Bruker AV 300 NMR spectrometer in chloroform-d or dimethyl sulfoxide-d 6 . The zeta potential measurement was performed on a Zeta Potential/BI-90Plus particle size analyzer (Brookhaven Instruments Corporation, USA). Dynamic laser scattering (DLS) was tested by a WyattQELS instrument with a vertically polarized HeNe laser (Dawn EOS, Wyatt Technology, USA). The scattering angle was fixed at 90°. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay was tested on a microplate reader (INFINITE 200 PRO, USA). Electrospray ionization mass spectrometry (ESI-MS) was detected using a Thermo LTQ XL ion trap mass spectrometer (Thermo Finnigan, USA) in a negative ion mode (ESI − ). The fluorescence intensity was performed on fluorescence master system (Photon Technology International, USA). The high performance liquid chromatography (HPLC) analyses were measured on a Waters 1525 system equipped with a reverse-phase column (Symme-try®C18). Acetonitrile and water (v/v = 4:1) were selected as the elution, pumped at a flow velocity of 1.0 mL min −1 at 25°C. 
Cell lines and animals
Synthesis of HNK-DMXAA
The HNK-DMXAA conjugate was synthesized by Steglich esterification reaction. Specially, HNK (1.1 eq.), DMXAA (1.0 eq.), DIC (1.0 eq.) and DMAP (0.1 eq.) were dissolved into anhydrous dichloromethane (DCM), and stirred for 48 h in dark at room temperature. The product was isolated through silica gel column chromatography with eluent of DCM:petrol puriss (PE) = 1:50. The solvent was then removed by vacuum rotary evaporation.
Synthesis of PALA-g-mPEG
PALA-g-mPEG was synthesized as previously described with slight modification [27] . Briefly, ALA was added into a dry flask under a nitrogen atmosphere and stirred at 90°C for 1.5 h. Then tetrahydrofuran (THF) was added to dissolve the crude product, and the product solution was slowly dripped into 10-fold volume of diethyl ether and precipitated for thrice. All the solvents were removed under vacuum to obtain dry PALA. Then, PALA (5.0 eq. on the base of ALA) was dissolved in THF. Meanwhile, mPEG 5k -OH (1.0 eq.), EDC·HCl (1.1 eq.) and DMAP (0.2 eq.) were dissolved in dimethyl sulfoxide (DMSO), then mixed with PALA, and stirred for 36 h at 30°C. The reaction mixture was dialyzed using a dialysis bag (MWCO 7.0 kDa) against deionized water for 24 h, and PALA-g-mPEG was obtained after lyophilization.
Synthesis of H-D NPs
The HNK-DMXAA was grafted to the prepared PALA-g-mPEG by Steglich esterification. Briefly, PALA-g-mPEG, HNK-DMXAA and DIC were added in anhydrous N,Ndimethylformamide (DMF) and stirred for 48 h in dark at room temperature. The reaction mixture was slowly precipitated by 10 times volume of diethyl ether to obtain a beige-white product. After being resolved with DMF, the crude product was precipitated into diethyl ether again and the solvents were removed by vacuum filtration. Next, the crude product was dissolved in DMF and dialyzed against deionized water for 12 h in dark. Zeta potential and GSH-responsiveness PALA-g-mPEG (1.0 mg mL −1 ) and H-D NPs (1.0 mg mL −1 ) were dissolved in deionized water, and then measured by the zeta potential analyzer. To measure the responsiveness of the nanomedicine, the H-D NPs (2.0 mg mL −1 ) were dissolved in phosphate buffered saline (PBS, pH 7.4, 100.0 mmol L −1 ) with or without 5.0 mmol L −1 GSH, shaken at 37°C for 0 or 24 h, and then the sizes were measured by DLS. To study the GSH response of the nanomedicine more intuitively, further characterization was performed by transmission electron microscopy (TEM) as well.
In vitro release
In vitro releases of HNK and DMXAA from the H-D NPs were tested using a dialysis method. Briefly, PBS (100.0 mmol L −1 ) and PBS (100.0 mmol L −1 ) containing GSH (0.1, 1.0, 5.0 mmol L −1 ) were used as the release media. H-D NPs (5.0 mg) were dissolved with 5.0 mL different release media. Next, the samples were transferred into the dialysis bags (MWCO 3.5 kDa), shaken in 45.0 mL release media with 85 r min −1 at 37°C. At 0, 2, 4, 8, 12 and 24 h, 3.0 mL of outside solution was taken out and then 3.0 mL fresh media was added. The accumulative releases of HNK and DMXAA were monitored by FLD-HPLC with two channels fluorescence detector at 220 nm E x and 380 nm E m for HNK, or at 345 nm E x and 409 nm E m for DMXAA at real time, with the elution of acetonitrile and water (v/v = 4:1) pumped at flow velocity of 1.0 mL min −1 at 25°C, as described above.
In vitro cytotoxicity and cell apoptosis analysis
The cytotoxicity in vitro was tested by MTT assay. 4T1 or HUVEC cells were seeded in 96-well culture plates (5.0 × respectively. Next, 20 μL of the solutions were added to each well and allowed to incubate for 24 h. After that, 20 μL of 5 mg mL −1 MTT in PBS was added to each well, and the cells were incubated for additional 3 min in dark at 37°C. All the DMEM were emptied completely and 150 μL DMSO was added to each well subsequently and shocked for 3 min. The absorbance of the solution was measured on the microplate reader at 490 nm. The relative cell viability was determined by comparing the absorbance of treated cells at 490 nm to non-treatment control wells. Data were presented as mean ± SD (n = 3). As for the cell apoptosis analysis, 4T1 cells were seeded in 6-well culture plates (1.0 × 10 5 per well) with 1.8 mL DMEM and 0.2 mL FBS per well, then allowed to adhere for 12 h. 100 μL of PBS, HNK (63 μmol L −1 ), DMXAA (63 μmol L −1 ) and H-D NPs (63 μmol L −1 on the basis of HNK) were added to each well and allowed to incubate for 24 h, respectively. After that, the apoptotic of 4T1 cells was tested by Annexin V-FITC/PI apoptosis detecting kit and flow cytometry.
Anti-tumor efficiency in vivo
The Balb/c mice breast tumor model was constructed by subcutaneous injection of 4T1 cells (2.0 × 10 6 per mouse) into the right lower abdomen. The mice were divided into 5 groups (5 mice per group) randomly when the tumors grew up to about 120 mm 3 . The tumor size and body weight were measured every other day, and the tumor volume was calculated as V = a × b 2 / 2 (a: the maximum diameter of tumors; b: the minimum diameter of tumors).
H & E and immunohistochemical staining
Two days after the last injection of anti-tumor efficiency test, the mice were sacrificed. Meanwhile, tumors were excised and fixed in 4% PBS-buffered formaldehyde (w/v) for 48 h, embedded in paraffin and sliced at 5 μm, then stained with haematoxylin and eosin (H & E) or CD31. As for CD31 staining, these fractions were in turn dewaxed and rehydrated with xylene, a series of graded ethanol, and deionized water. Endogenous peroxidase was quenched with 3% hydrogen peroxide for 15 min. Next, the sliced samples were rinsed with deionized water, dipped in boiled citric buffer for 10 min, blocked with blocking buffer (5% normal goat serum) for 1.5 h. And the slides were incubated with rabbit anti-CD31 (1:100) polyclonal antibody at 4°C overnight. After washing by PBS, goat anti-rabbit IgG (1:1000) was added and incubated for 1 h at 25°C. The sections were stained by diaminobenzidine (DAB), counterstained with hematoxylin and mounted with mounting medium in proper sequence. The section stained brown showed CD31 positive.
TUNEL assay
TUNEL assay was measured according to the manufacturer's instructions on the TUNEL kit. And the apoptosis was measured by fluorescence microscopy.
Statistical analysis
Statistical analysis (n = 3) was expressed as the mean ± SD standard deviation, using the One Way Anova. Statistically significant was expressed using * (p < 0.05), highly significant was expressed using ** (p < 0.01) and extremely significant was expressed using *** (p < 0.001).
RESULTS AND DISCUSSION
Synthesis of HNK-DMXAA
The HNK-DMXAA conjugate was characterized by 1 H NMR and ESI-MS in chloroform-d after isolated through silica gel chromatography column. As shown in Fig. S1 , peak e of HNK-DMXAA shifted from δ 3.85 ppm in DMXAA (Fig. S2) to δ 4.02 ppm, indicating that the HNK-DMXAA was successfully synthesized, and this was further confirmed by ESI-MS (Fig. S3) , where the HNK-DMXAA exhibited a peak at m/z = 529.6 for [M−H] − , while the m/z = 530.5 was caused by isotopic molecules. This result indicated that the HNK-DMXAA conjugate was synthesized as expected.
Synthesis of PALA-g-mPEG
After ROP of alpha-lipoic acid monomer, PALA and PALA-g-mPEG were obtained and characterized by 1 H NMR in DMSO-d 6 . As shown in Fig. 2 , as the dithiolane ring of ALA opened, peak a and c became overlapped, and peak l of mPEG appeared in PALA-g-mPEG after dialysis against deionized water for 24 h, indicated that PALA was successfully synthesized and bonded to mPEG. The integral ratio of peak b to peak l in PALA-g-mPEG was 1:45, indicating that the mass ratio of PALA to mPEG was 5:1.
Synthesis of H-D NPs
The H-D NPs were characterized by 1 H NMR in DMSOd 6 . In Fig. 2 , there appeared obvious benzene ring peaks from δ 7.20 to 8.60 ppm, indicating that PALA-g-mPEG had successfully bonded to HNK-DMXAA. The DLC of HNK and DMXAA of H-D NPs was determined by FLD-HPLC. As shown in Fig. 3 , when fluorescence detector was set at 220 nm E x and 380 nm E m , DMXAA only had a weak fluorescence signal at 4.60 min, while HNK had a strong fluorescence signal at 7.06 min. When fluorescence detector was set at 345 nm E x and 409 nm E m , no fluorescence signal was found in HNK, while DMXAA had strong fluorescence signal in 4.56 min. On this basis, we determined the DLC of HNK and DMXAA in the H-D NPs were 5.3 wt% and 4.7 wt%, respectively. The slight difference in molar ratio (1.19:1) may be due to the partial cleavage of the conjugate of HNK and DMXAA during dialysis purification.
Zeta potential
The zeta potential of PALA-g-mPEG was (−18.5 ± 4.9) mV, while the zeta potential of the H-D NPs changed to (−12.8 ± 5.8) mV, because the HNK-DMXAA bonding reduced the number of carboxyl group on PALA-g-mPEG. This further demonstrated that the H-D NPs were obtained successfully.
GSH-responsiveness
In order to verify the GSH responsiveness of the nanomedicine, H-D NPs were dissolved in PBS (1.0 mg mL −1 ) under different GSH concentrations. As shown in Fig. 4a , the hydrodynamic radius (R h ) of the H-D NPs in PBS was (57.1 ± 10.1) nm, and it became (74.4 ± 21.4) nm after 24 h, while the radius in PBS with 5.0 mmol L −1 GSH changed to (125.9 ± 73.5) nm, which revealed the great GSH response ability of the nanomedicine. Meanwhile, to demonstrate the GSH response of the nanomedicine more intuitively, TEM measurement was carried out, which indicated that the average diameter of the H-D NPs in PBS (Fig. 4b) was about (117.2 ± 12.0) nm, while the disintegration of H-D NPs in Fig. 4c was obvious at the presence of 5.0 mmol L −1 GSH. The change of particle sizes also proved that the H-D NPs had excellent re- sponsiveness to GSH.
In vitro release
To simulate the drug releases in the treatment, HNK and DMXAA releases in vitro at different GSH concentrations were measured. As shown in Fig. 5 , the releases of both HNK and DMXAA increased with the disintegration of the H-D NPs by GSH. The HNK release in PBS with 5.0 mmol L −1 GSH was 2.89-fold higher than that in PBS without GSH, while the DMXAA release in PBS with 5.0 mmol L −1 GSH increased 2.75-fold higher than that in PBS without GSH. With the increase of GSH concentration, the drug release rate also increased, indicating the GSH responsive release of the nanomedicine.
Cytotoxicity and cell apoptosis analysis
To understand the cytotoxicity of drugs on cancer cells and vascular endothelial cells, 4T1 and HUVEC were used for MTT assay. As shown in Fig. 6 , HNK, as a cytotoxic drug, had obvious cytotoxicity to both cell lines, with a half maximal inhibitory concentration (IC 50 ) of 11.5 μmol L −1 to 4T1 and IC 50 of 12.0 μmol L −1 to HU-VEC. In contrast to HNK, DMXAA has inhibition at high concentrations on HUVEC cells, but no effect on 4T1 cells was exhibited. In addition, HNK-DMXAA exhibited similar cytotoxicity to HNK, with an IC 50 of 12.3 μmol L 
Anti-tumor efficiency in vivo
Owing to the excellent results in vitro, we were looking forward to the anti-tumor effect of H-D NPs in vivo. 4T1 model was chosen for anti-tumor efficacy research. As shown in Fig. 7 , except PBS group, the tumor volumes all decreased, and only the group of small molecule drugs combination showed significant change in body weight during the treatment, and the inhibition rate of this group was 82.6%, which was higher than 13.4% of HNK and 76.6% of DMXAA. As expected, H-D NPs had the strongest therapeutic effect and the inhibition rate was 93.0%, which was significantly higher than other groups.
H & E staining
To further study the effects of each drug on tumors, tumors after treatment were stained with H & E for pathological analysis. As shown in Fig. 8a -e, the tumor treated with PBS had large cell nuclei and abundant cytoplasm, indicating that the tumor had strong ability to proliferate. The tumor treated with HNK exhibited small cell nuclei and the morphology was abnormal, which revealed the cytotoxicity of HNK. In the DMXAA treatment group, the necrosis of the central part of the tumor was serious, indicating that the blocking effect of DMXAA on blood vessels blocked the supply of the tumors and led to large necrosis area of the central cells in the tumor. The combination of HNK and DMXAA small molecules demonstrated the death of both internal and external tumors. Best of all, the tumor treated with H-D NPs exhibited the largest area of cell death and abnormal cell morphology, which also made the group of H-D NPs have the best anti-tumor efficacy.
Immunohistochemical staining and TUNEL assay
In order to study the effect of treatment on tumor vessels, we performed a pathological analysis of CD31 staining. For CD31 staining, the blood vessels were thick and rich in PBS group (Fig. 8f) . HNK group showed a slight inhibition of vascular growth (Fig. 8g ), while the vascular inhibition was obvious in the DMXAA group (Fig. 8h) , the combination group of small molecules (HNK and DMXAA) ( Fig. 8i ) and H-D NPs group (Fig. 8j ). Among them, H-D NPs group had the lowest mean vessel density, which was 19-fold lower than that in PBS group (Fig. S5 ).
To evaluate whether tumor growth inhibition was related to apoptosis, TUNEL staining was performed. As seen in Fig. S6 , the tumors injected with H-D NPs exhibited high populations of apoptotic cells than PBS group.
